Quest Diagnostics Incorporated (DGX) Director Sells $141,783.92 in Stock

Quest Diagnostics Incorporated (NYSE:DGX) Director Jeffrey M. Leiden sold 1,304 shares of Quest Diagnostics stock in a transaction on Thursday, July 27th. The shares were sold at an average price of $108.73, for a total value of $141,783.92. Following the completion of the transaction, the director now owns 6,296 shares of the company’s stock, valued at approximately $684,564.08. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Quest Diagnostics Incorporated (NYSE DGX) opened at 104.87 on Friday. The firm has a market capitalization of $14.30 billion, a PE ratio of 21.13 and a beta of 0.69. The firm has a 50-day moving average price of $108.23 and a 200-day moving average price of $103.54. Quest Diagnostics Incorporated has a 1-year low of $79.12 and a 1-year high of $112.96.

Quest Diagnostics (NYSE:DGX) last issued its quarterly earnings results on Tuesday, July 25th. The medical research company reported $1.55 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.42 by $0.13. Quest Diagnostics had a return on equity of 15.66% and a net margin of 9.28%. The firm had revenue of $1.94 billion during the quarter, compared to the consensus estimate of $1.94 billion. During the same period last year, the business posted $1.34 EPS. The business’s revenue was up 1.9% compared to the same quarter last year. Equities analysts expect that Quest Diagnostics Incorporated will post $5.69 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 18th. Shareholders of record on Tuesday, October 3rd will be issued a dividend of $0.45 per share. The ex-dividend date of this dividend is Monday, October 2nd. This represents a $1.80 dividend on an annualized basis and a yield of 1.72%. Quest Diagnostics’s payout ratio is currently 36.29%.

TRADEMARK VIOLATION WARNING: “Quest Diagnostics Incorporated (DGX) Director Sells $141,783.92 in Stock” was originally posted by BNB Daily and is the sole property of of BNB Daily. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this report can be accessed at https://www.baseball-news-blog.com/2017/08/19/quest-diagnostics-incorporated-dgx-director-jeffrey-m-leiden-sells-1304-shares-of-stock-updated-updated.html.

DGX has been the subject of several research analyst reports. UBS AG upgraded Quest Diagnostics from a “market perform” rating to an “outperform” rating in a research report on Friday, April 21st. Raymond James Financial, Inc. upgraded Quest Diagnostics from a “market perform” rating to an “outperform” rating and set a $116.00 price objective for the company in a research report on Friday, April 21st. Deutsche Bank AG reiterated a “buy” rating and issued a $115.00 price objective (up previously from $108.00) on shares of Quest Diagnostics in a research report on Sunday, April 23rd. Barclays PLC reiterated an “equal weight” rating and issued a $100.00 price objective (up previously from $98.00) on shares of Quest Diagnostics in a research report on Sunday, April 23rd. Finally, Evercore ISI restated an “in-line” rating and set a $104.50 target price (up previously from $102.00) on shares of Quest Diagnostics in a research report on Monday, April 24th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $109.62.

A number of hedge funds have recently modified their holdings of the company. WFG Advisors LP increased its stake in shares of Quest Diagnostics by 45.3% in the second quarter. WFG Advisors LP now owns 966 shares of the medical research company’s stock valued at $107,000 after buying an additional 301 shares in the last quarter. Sun Life Financial INC increased its stake in shares of Quest Diagnostics by 14,142.9% in the second quarter. Sun Life Financial INC now owns 997 shares of the medical research company’s stock valued at $111,000 after buying an additional 990 shares in the last quarter. YorkBridge Wealth Partners LLC increased its stake in shares of Quest Diagnostics by 1.5% in the first quarter. YorkBridge Wealth Partners LLC now owns 1,188 shares of the medical research company’s stock valued at $127,000 after buying an additional 18 shares in the last quarter. Parallel Advisors LLC increased its stake in shares of Quest Diagnostics by 16.1% in the first quarter. Parallel Advisors LLC now owns 1,279 shares of the medical research company’s stock valued at $137,000 after buying an additional 177 shares in the last quarter. Finally, Advisors Capital Management LLC purchased a new stake in shares of Quest Diagnostics during the first quarter valued at approximately $164,000. Hedge funds and other institutional investors own 90.06% of the company’s stock.

Quest Diagnostics Company Profile

Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs).

Insider Buying and Selling by Quarter for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply